Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Bio-Path Holdings unveils preclinical success for BP1001-A in treating obesity and Type 2 diabetes Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology innovator known for leveraging its DNAbilize liposomal delivery platform, has announced… byPallavi MadhirajuDecember 19, 2024